206 related articles for article (PubMed ID: 34240545)
21. Hematopoietic stem cell gene therapy for adenosine deaminase-deficient severe combined immunodeficiency leads to long-term immunological recovery and metabolic correction.
Gaspar HB; Cooray S; Gilmour KC; Parsley KL; Zhang F; Adams S; Bjorkegren E; Bayford J; Brown L; Davies EG; Veys P; Fairbanks L; Bordon V; Petropoulou T; Kinnon C; Thrasher AJ
Sci Transl Med; 2011 Aug; 3(97):97ra80. PubMed ID: 21865538
[TBL] [Abstract][Full Text] [Related]
22. Gene therapy of primary T cell immunodeficiencies.
Fischer A; Hacein-Bey-Abina S; Cavazzana-Calvo M
Gene; 2013 Aug; 525(2):170-3. PubMed ID: 23583799
[TBL] [Abstract][Full Text] [Related]
23. Gene therapy for inherited immunodeficiency.
Touzot F; Hacein-Bey-Abina S; Fischer A; Cavazzana M
Expert Opin Biol Ther; 2014 Jun; 14(6):789-98. PubMed ID: 24823313
[TBL] [Abstract][Full Text] [Related]
24. EMA greenlights second gene therapy.
Mullard A
Nat Rev Drug Discov; 2016 May; 15(5):299. PubMed ID: 27139988
[No Abstract] [Full Text] [Related]
25. A case of T-cell acute lymphoblastic leukemia in retroviral gene therapy for ADA-SCID.
Cesana D; Cicalese MP; Calabria A; Merli P; Caruso R; Volpin M; Rudilosso L; Migliavacca M; Barzaghi F; Fossati C; Gazzo F; Pizzi S; Ciolfi A; Bruselles A; Tucci F; Spinozzi G; Pais G; Benedicenti F; Barcella M; Merelli I; Gallina P; Giannelli S; Dionisio F; Scala S; Casiraghi M; Strocchio L; Vinti L; Pacillo L; Draghi E; Cesana M; Riccardo S; Colantuono C; Six E; Cavazzana M; Carlucci F; Schmidt M; Cancrini C; Ciceri F; Vago L; Cacchiarelli D; Gentner B; Naldini L; Tartaglia M; Montini E; Locatelli F; Aiuti A
Nat Commun; 2024 Apr; 15(1):3662. PubMed ID: 38688902
[TBL] [Abstract][Full Text] [Related]
26. Gene therapy for PIDs: progress, pitfalls and prospects.
Mukherjee S; Thrasher AJ
Gene; 2013 Aug; 525(2):174-81. PubMed ID: 23566838
[TBL] [Abstract][Full Text] [Related]
27. [Transplantation of genetically modified cells in the treatment of children with SCID: great hopes and recent disappointments].
Smogorzewska EM; Weinberg KI; Kohn DB
Med Wieku Rozwoj; 2003; 7(1):27-34. PubMed ID: 13130167
[TBL] [Abstract][Full Text] [Related]
28. A Journey in the Development of Gene Therapy for Inherited Disorders of the Bone Marrow.
Kohn D; Wilson JM
Hum Gene Ther Clin Dev; 2015 Dec; 26(4):203-7. PubMed ID: 26684443
[No Abstract] [Full Text] [Related]
29. Gene therapy for adenosine deaminase severe combined immune deficiency-An unexpected journey of four decades.
Kohn DB
Immunol Rev; 2024 Mar; 322(1):148-156. PubMed ID: 38033164
[TBL] [Abstract][Full Text] [Related]
30. Effects of vector backbone and pseudotype on lentiviral vector-mediated gene transfer: studies in infant ADA-deficient mice and rhesus monkeys.
Carbonaro Sarracino D; Tarantal AF; Lee CC; Martinez M; Jin X; Wang X; Hardee CL; Geiger S; Kahl CA; Kohn DB
Mol Ther; 2014 Oct; 22(10):1803-16. PubMed ID: 24925206
[TBL] [Abstract][Full Text] [Related]
31. Long-Term Outcome of Adenosine Deaminase-Deficient Patients-a Single-Center Experience.
Scott O; Kim VH; Reid B; Pham-Huy A; Atkinson AR; Aiuti A; Grunebaum E
J Clin Immunol; 2017 Aug; 37(6):582-591. PubMed ID: 28748310
[TBL] [Abstract][Full Text] [Related]
32. Hematopoietic stem cell transplantation rescues the immunologic phenotype and prevents vasculopathy in patients with adenosine deaminase 2 deficiency.
Van Eyck L; Hershfield MS; Pombal D; Kelly SJ; Ganson NJ; Moens L; Frans G; Schaballie H; De Hertogh G; Dooley J; Bossuyt X; Wouters C; Liston A; Meyts I
J Allergy Clin Immunol; 2015 Jan; 135(1):283-7.e5. PubMed ID: 25457153
[No Abstract] [Full Text] [Related]
33. Alterations in the adenosine metabolism and CD39/CD73 adenosinergic machinery cause loss of Treg cell function and autoimmunity in ADA-deficient SCID.
Sauer AV; Brigida I; Carriglio N; Hernandez RJ; Scaramuzza S; Clavenna D; Sanvito F; Poliani PL; Gagliani N; Carlucci F; Tabucchi A; Roncarolo MG; Traggiai E; Villa A; Aiuti A
Blood; 2012 Feb; 119(6):1428-39. PubMed ID: 22184407
[TBL] [Abstract][Full Text] [Related]
34. Built to last: gene therapy for ADA SCID.
Pai SY
Blood; 2021 Oct; 138(15):1287-1288. PubMed ID: 34647983
[No Abstract] [Full Text] [Related]
35. Twenty-Five Years of Gene Therapy for ADA-SCID: From Bubble Babies to an Approved Drug.
Ferrua F; Aiuti A
Hum Gene Ther; 2017 Nov; 28(11):972-981. PubMed ID: 28847159
[TBL] [Abstract][Full Text] [Related]
36. Treatment of severe combined immunodeficiency disease (SCID) due to adenosine deaminase deficiency with CD34+ selected autologous peripheral blood cells transduced with a human ADA gene. Amendment to clinical research project, Project 90-C-195, January 10, 1992.
Blaese RM; Culver KW; Chang L; Anderson WF; Mullen C; Nienhuis A; Carter C; Dunbar C; Leitman S; Berger M
Hum Gene Ther; 1993 Aug; 4(4):521-7. PubMed ID: 7691188
[TBL] [Abstract][Full Text] [Related]
37. Drug evaluation: ADA-transduced hematopoietic stem cell therapy for ADA-SCID.
Taupin P
IDrugs; 2006 Jun; 9(6):423-30. PubMed ID: 16752313
[TBL] [Abstract][Full Text] [Related]
38. Adenosine deaminase type 2 deficiency masquerading as GATA2 deficiency: Successful hematopoietic stem cell transplantation.
Hsu AP; West RR; Calvo KR; Cuellar-Rodriguez J; Parta M; Kelly SJ; Ganson NJ; Hershfield MS; Holland SM; Hickstein DD
J Allergy Clin Immunol; 2016 Aug; 138(2):628-630.e2. PubMed ID: 27130863
[No Abstract] [Full Text] [Related]
39. Consensus approach for the management of severe combined immune deficiency caused by adenosine deaminase deficiency.
Kohn DB; Hershfield MS; Puck JM; Aiuti A; Blincoe A; Gaspar HB; Notarangelo LD; Grunebaum E
J Allergy Clin Immunol; 2019 Mar; 143(3):852-863. PubMed ID: 30194989
[TBL] [Abstract][Full Text] [Related]
40. Evolving Gene Therapy in Primary Immunodeficiency.
Thrasher AJ; Williams DA
Mol Ther; 2017 May; 25(5):1132-1141. PubMed ID: 28366768
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
